GSDME and acute myeloid leukemia: Moreover, GSDME is downregulated in AML, and GSDME downregulation is associated with poor prognosis, suggesting that GSDME expression is a potential prognostic biomarker and that modulation of GSDME expression is a therapeutic strategy for AML.